Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ChronoScale Holdings CorpEKSO · Entity 4331 | Director | November 10, 2020 | November 12, 2020 |
| MariaDB plcMRDB · Entity 86860 | Director | June 29, 2023 | June 30, 2023 |
| ViewRay, Inc.VRAY · Entity 111118 | Director | January 02, 2019 | January 03, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ChronoScale Holdings Corp
Report date November 10, 2020 · Filed November 12, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Puissance Cross-Border Opportunities II LLC | 29,828 |
Reported balance
After 2020-11-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-11-10 · Other · Disposed 744,572 · Balance 29,828 F1: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 744,572 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests. F2: These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Common StockSEC Table I · non-derivative | Direct | 9,958 |
Reported balance
Holding disclosure · report date 2020-11-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 9,958 |
Filing footnotes · ownership attribution and instrument terms
F1: Puissance Cross-Border Opportunities II LLC made an in-kind distribution of an aggregate 744,572 shares of the Issuer's common stock to one of its limited partners in connection with the redemption of partnership interests.
F2: These securities are held directly by Puissance Cross-Border Opportunities II LLC and may be deemed to be beneficially owned by Puissance Capital Management LP, the investment manager of Puissance Cross Border Opportunities II LLC; Puissance Capital Management (GP) LLC, the general partner of Puissance Capital Management LP; Puissance Capital Fund (GP) LLC, the general partner of Puissance Cross Border Opportunities II LLC; and Theodore T. Wang, the managing member of Puissance Capital Management (GP) LLC and Puissance Capital Fund (GP) LLC. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person is the beneficial owner of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
MariaDB plc
Report date June 29, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 2,659,568 |
Reported balance
After 2023-06-29 transaction · row 1
1 source rowRow 1 · 2023-06-29 · Grant · Acquired 182,291 · Balance 2,659,568 F1: Represents a restricted stock unit award that will fully vest upon the earlier of (i) the one-year anniversary of the grant date and (ii) the day immediately prior to the Company's annual meeting of shareholders that next occurs after the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit award that will fully vest upon the earlier of (i) the one-year anniversary of the grant date and (ii) the day immediately prior to the Company's annual meeting of shareholders that next occurs after the grant date.
ViewRay, Inc.
Report date January 02, 2019 · Filed January 03, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,117 |
Ending reported balance
After 2019-01-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-01-02 · Grant · Acquired 7,305 · Balance 15,449 F1: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan or (iii) January 2, 2029 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2019 such that 100% of the DSUs will be vested on December 31, 2019, subject to the Reporting Person remaining a service provider through each such vesting date. F2: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $45,000. Row 2 · 2019-01-02 · Grant · Acquired 18,668 · Balance 34,117 F3: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on January 2, 2020 (the one-year anniversary of the grant date), subject to the Reporting Person remaining a service provider through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities are DSUs that entitle the Reporting Person to receive one share of Common Stock per DSU upon the earliest of (i) the Reporting Person's termination of service from the Issuer's board of directors, (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan or (iii) January 2, 2029 (the tenth anniversary of the grant date). 1/12th of these DSUs shall vest on the last day of each calendar month beginning on January 31, 2019 such that 100% of the DSUs will be vested on December 31, 2019, subject to the Reporting Person remaining a service provider through each such vesting date.
F2: These DSUs were issued to the reporting person pursuant to ViewRay Inc.'s Non-Employee Director Compensation Policy in lieu of retainer and committee service fees of $45,000.
F3: The reported securities are RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon vesting. All of these RSUs shall vest on January 2, 2020 (the one-year anniversary of the grant date), subject to the Reporting Person remaining a service provider through such date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Angel Pond Holdings Corp
Report date December 16, 2022 · Filed December 19, 2022
Jointly reported with Xie Shihuang, Lionyet International Ltd.
Section 16 reporting ended · disclosed 2022-12-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | IndirectSee Explanation of Responses | 0 |
Reported balance
After 2022-12-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-16 · Other · Disposed 6,637,870 · Balance 0 F1: Disposed of pursuant to the business combination agreement dated January 31, 2022 (the "BCA") between MariaDB plc (formerly named Mangomill plc, the "Company") and Angel Pond Holdings Corp. ("APHC") in exchange for ordinary shares, nominal value $0.01 per share, of the Company (the "Combined Company Ordinary Shares"). F2: As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer would automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. On December 16, 2022, each share of Class B common stock, par value $0.0001 per share, of APHC owned by the reporting persons were cancelled and converted into the right to receive one Combined Company Ordinary Shares, subject to the terms and conditions of the BCA. F3: Shihuang Xie is the director of Lionyet International Ltd. Lionyet International Ltd and Theodore Wang are the co-managing members of Angel Pond Partners LLC and together exercised voting and investment power with respect to the Class B ordinary shares, par value $0.0001 per share, held by Angel Pond Partners LLC. The shares beneficially owned by Angel Pond Partners LLC may have been deemed to be beneficially owned by Mr. Xie, Lionyet International Ltd. and Theodore Wang. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the business combination agreement dated January 31, 2022 (the "BCA") between MariaDB plc (formerly named Mangomill plc, the "Company") and Angel Pond Holdings Corp. ("APHC") in exchange for ordinary shares, nominal value $0.01 per share, of the Company (the "Combined Company Ordinary Shares").
F2: As described in the issuer's registration statement on Form S-1 (File No. 333-253990), as amended, under the heading "Description of Securities--Founder Shares," the Class B ordinary shares, par value $0.0001 per share, of the issuer would automatically convert into Class A ordinary shares, par value $0.0001 per share, of the issuer at the time of, or immediately following, the issuer's initial business combination, on a one-for-one basis, subject to certain adjustments, and have no expiration date. On December 16, 2022, each share of Class B common stock, par value $0.0001 per share, of APHC owned by the reporting persons were cancelled and converted into the right to receive one Combined Company Ordinary Shares, subject to the terms and conditions of the BCA.
F3: Shihuang Xie is the director of Lionyet International Ltd. Lionyet International Ltd and Theodore Wang are the co-managing members of Angel Pond Partners LLC and together exercised voting and investment power with respect to the Class B ordinary shares, par value $0.0001 per share, held by Angel Pond Partners LLC. The shares beneficially owned by Angel Pond Partners LLC may have been deemed to be beneficially owned by Mr. Xie, Lionyet International Ltd. and Theodore Wang.
Bellerophon Therapeutics, Inc.
Report date October 13, 2023 · Filed October 16, 2023
Jointly reported with Puissance Capital Management LP, Puissance Life Science Opportunities Fund VI, Puissance Capital Fund (GP) LLC
Section 16 reporting ended · disclosed 2023-10-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-10-13 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-10-13 · Sale · Disposed 1,076,841 · Balance 0 |
Tracon Pharmaceuticals, Inc.
Report date December 05, 2019 · Filed December 11, 2019
Jointly reported with Puissance Cross-Border Opportunities V LLC, Puissance Cross-Border Opportunities IV LLC, Puissance Capital Management LP, Puissance Capital Fund (GP) LLC, Puissance Capital Management (GP) LLC
Section 16 reporting ended · disclosed 2019-12-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy funds | 416,182 |
Reported balance
After 2019-12-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-12-05 · Sale · Disposed 43,996 · Balance 416,182 F1: Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 43,996 shares of common stock. F2: Consists of: 239,190 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Shares directly owned Puissance Cross-Border Opportunities IV LLC. |
| Common StockSEC Table I · non-derivative | IndirectBy funds | 76,048 |
Reported balance
After 2019-12-09 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2019-12-09 · Sale · Disposed 340,134 · Balance 76,048 F3: Puissance Cross-Border Opportunities IV LLC made an in-kind distribution of 176,992 shares of common stock. Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 163,142 shares of common stock. F4: Consists of: 76,048 Shares directly owned by Puissance Cross-Border Opportunities V LLC. |
| Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.00 · Expires 2024-03-27 | IndirectBy funds | 460,178 |
Reported balance
Holding disclosure · report date 2019-12-05 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 460,178 F5: Consists of: 283,186 Warrants directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Warrants directly owned Puissance Cross-Border Opportunities IV LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 43,996 shares of common stock.
F2: Consists of: 239,190 Shares directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Shares directly owned Puissance Cross-Border Opportunities IV LLC.
F3: Puissance Cross-Border Opportunities IV LLC made an in-kind distribution of 176,992 shares of common stock. Puissance Cross-Border Opportunities V LLC made an in-kind distribution of 163,142 shares of common stock.
F4: Consists of: 76,048 Shares directly owned by Puissance Cross-Border Opportunities V LLC.
F5: Consists of: 283,186 Warrants directly owned by Puissance Cross-Border Opportunities V LLC; 176,992 Warrants directly owned Puissance Cross-Border Opportunities IV LLC.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2018 Filed Jun 7, 2018 16:44 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 38,216 | $2.27 Strike: $2.27 | $86,750.32 |
DisclosureSEC source: 0001600132-18-000066 · wf-form4_152840427506208.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,216 Underlying: Common Stock · 38,216 shares Expires 2028-06-04 Read SEC document |
| April 06, 2018 Filed Apr 9, 2018 20:53 UTC | Tracon Pharmaceuticals, Inc. TCON · Entity 91134 | GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001209191-18-024455 · doc4.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-05 F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable in three equal annual installments commencing on the first anniversary of the grant date set forth in column 3 above. Read SEC document |
| December 12, 2017 Filed Dec 14, 2017 16:34 UTC | Bellerophon Therapeutics, Inc. BLPH · Entity 108982 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001600132-17-000136 · wf-form4_151328727965670.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-12-11 F1 · derivative.exercise_date: This option vests in three equal annual installments over a three-year period from the date of Dr. Wang's board appointment on November 27, 2017. Read SEC document |
| November 15, 2017 Filed Apr 26, 2018 17:24 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantStock Option (right to buy) · Derivative | 18,459 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0000950103-18-005219 · dp89954_4-wang.xml · derivative · entry 2 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,459 Underlying: Common Stock · 18,459 shares Expires 2027-11-15 F3 · derivative.exercise_date: 1/12 of the shares subject to the option vested and became exercisable on each monthly anniversary measured from June 19, 2017, such that 100% of the shares subject to the option will fully vest on June 19, 2018. Read SEC document |
| November 15, 2017 Filed Apr 26, 2018 17:24 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantCommon Stock | 3,408 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-18-005219 · dp89954_4-wang.xml · nonDerivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,408 F1 · shares: Restricted Stock Units ("RSUs"). The reported securities are fully vested RSUs that entitle the Reporting Person to receive one share of Common Stock per RSU upon the earlier of (i) the Reporting Person's termination of service from the Issuer's board of directors or (ii) a Change of Control of the Issuer as defined in the Issuer's 2015 Equity Incentive Award Plan. F2 · balance_after: Consists of RSUs. Read SEC document |
| January 24, 2017 Filed Jan 25, 2017 17:57 UTC | ViewRay, Inc. VRAY · Entity 111118 | GrantStock Option (right to buy) · Derivative | 19,556 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001140361-17-002908 · doc1.xml · derivative · entry 1 Wang Theodore T · CIK 0001694061 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,556 Underlying: Common Stock · 19,556 shares Expires 2027-01-24 F1 · derivative.exercise_date: The shares subject to the option vest in 12 monthly installments on each monthly anniversary of January 24, 2017 until such shares subject to the option have become fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.